Prof. Dr. med. Hans Christian Reinhardt

Curriculum vitae

Academic education

  • 1996 - 2003: Medical School, University of Hamburg, Humboldt University Berlin and University of Freiburg

Scientific degrees

  • 05/2020: Professor for Internal Medicine, Hematology and Stem Cell Transplantation (W3) and Director of the Department of Hematology and Stem Cell Transplantation, University Hospital Essen
  • 2012 - 2020 : Professor for Clinical and Molecular Oncology (W2), University Hospital Cologne
  • 2008: Habilitation in Experimental Internal Medicine, University of Cologne
  • 2003: MD thesis, Department of Internal Medicine, Division 4, University of Freiburg, Advisor: Prof. Dr. H. Pavenstädt (Grade: Summa cum laude)
  • 2003: Graduation from Medical School, University of Freiburg (Grade: Summa cum laude)

Scientific career

  • since 2020: Professor for Hematology and Stem Cell Transplantation (W3), University Hospital Essen
  • since 2020: Director Department of Hematology and Stem Cell Transplantation, University Hospital Essen
  • since 2020: Elected member of the board of the Competence Network Malignant Lymphoma
  • 2020: Co-founder CDL Therapeutics GmbH
  • since 2019: Elected member of the certification committee of the German Cancer Society (Zertifizierungskommission der Deutschen Krebsgesellschaft) for hematological malignancies
  • since 2019: Elected Vice-Speaker of the network of Mildred Scheel Schools of Oncology (Hamburg, Würzburg, Dresden, Frankfurt, Köln-Bonn)
  • since 2019: Co-Speaker Collaborative Research Center "Mechanisms of Drug Sensitivity and Resistance in Small Cell Lung Cancer" (SFB-1399)
  • 2018 - 2020: Speaker of the Mildred Scheel School of Oncology Cologne-Bonn: Cancer- and Immuno-genomics
  • since 2017: Speaker of the Else Kröner Research College: Clonal evolution in cancer
  • 2015 - 2020: Attending physician at the Department I of Internal Medicine of the University Hospital Cologne
  • 2015: Board exam (certified in general internal medicine and hematology and medical oncology)
  • 2015 - 2020: Elected member of the executive board of the Center for Molecular Medicine Cologne
  • 2013 - 2019: Head of the Clinical Research Unit-286 “Exploiting defects in the DNA damage response for the treatment of chronic lymphocytic leukemia”
  • 2012 - 2015: Elected member of the steering committee of the Helmholtz Alliance Preclinical Comprehensive Cancer Center(PCCC) and scientific coordinator of Research Topic 3, Hematological Malignancies within the PCCC
  • 2012 - 2020: Scientific coordinator of Research Area C (DNA damage response) within the Excellence Cluster CECAD
  • 2012 - 2020: Professor for Clinical and Molecular Oncology (W2), University Hospital Cologne
  • 2009 - 2015: Emmy-Noether research group leader at the Max-Planck-Institute Cologne and the Department I of Internal Medicine of the University Hospital Cologne
  • 2008: Habilitation for Molecular Medicine at the Medical Faculty of the University of Cologne
  • 2004 - 2009: Postdoctoral Associate, MIT, Department of Biology, Koch Institute, Advisors: Profs. M.B. Yaffe, MD, PhD and T. Jacks, PhD
  • 2004: Postdoctoral Research Fellow, University of Münster, Germany, Advisor: Prof. Dr. H. Pavenstädt.
  • 2003: Postdoctoral Research Fellow University of Freiburg, Germany, Advisor: Profs. Dr. G. Walz and Dr. T. Benzing

Honors/ Awards/ Memberships

  • 2021: Astra-Zeneca Scholar Award in Hematology Research
  • 2017: Gilead Research Award Oncology
  • 2016: Theodor Frerichs Award of the German Society of Internal Medicine
  • 2012: GlaxoSmithKline Research Award
  • 2011: Vincenz Czerny Award of the German Society for Hematology and Oncology
  • 2011: W2 Lichtenberg Professorship of the Volkswagen Stiftung
  • 2011: Research Award of the Central European Society for Anticancer Drug Research
  • 2011: Johann-Georg-Zimmermann Award for Cancer Research
  • 2010: Young Leaders in Science Award of the Schering Stiftung
  • 2009: Emmy-Noether fellowship of the Deutsche Forschungsgemeinschaft
  • 2009: Startup grant Ministerium für Innovation, Wissenschaft, Forschung und Technologie, NRW
  • 2009: NIH/NCI K99/R00 PI award (relinquished due to return to Germany)
  • 2007: MIT-Koch Award
  • 2005: Research fellowship of the Deutsche Forschungsgemeinschaft
  • 2004: Young investigator award of the Deutsche Nierenstiftung

10 most relevant publications

  1. Janes KA*, Reinhardt HC*, and Yaffe MB. Cytokine-induced signaling networks prioritize dynamic range over signal strength. Cell, 2008 Oct 17;135(2):343-54.*equal contribution
  2. Jachimowicz RD, Beleggia F, Isensee J, Bhavana VB, Goergens J, Bustos MA, Doll MA, Shenoy A, Checa-Rodriguez C, Wiederstein JL, Baranes-Bachar K, Bartenhagen C, Hertwig F, Teper N, Nishi T, Schmitt A, Distelmaier F, Lüdecke HJ, Albrecht B, Krüger M, Schumacher B, Geiger T, Hoon DSB, Huertas P, Fischer M, Hucho T, Peifer M, Ziv Y, Reinhardt HC*#, Wieczorek D*, Shiloh Y*: UBQLN4 represses homologous recombination and is overexpressed in aggressive tumors, Cell, 2019 Jan 24;176(3):505-519.e22,* Shared last authors, # lead author contact
  3. Dietlein F, Kalb B, Jokic M, Noll EM, Strong A, Tharun A, Ozretić L, Künstlinger H, Kambartel K, Randerath WJ, Jüngst C, Schmitt A, Torgovnick A, Richters A, Rauh D, Siedek F, Persigehl T, Mauch C, Bartkova J, Bradley A, Sprick MR, Trumpp A, Rad R, Saur D, Bartek J, Wolf J, Büttner R, Thomas RK, Reinhardt HC. A synergistic interaction between Chk1- and MK2 inhibitors in KRAS-mutant cancer. Cell, 2015 Jul 2; 1; 146-159
  4. Dietlein F, Thelen L, Jokic M, Jachimowicz RD, Ivan L, Knittel G, Leeser U, van Oers J, Edelmann W, Heukamp LC, Reinhardt HC. A functional cancer genomics screen identifies a druggable synthetic lethal interaction between MSH3 and PRKDC. Cancer Discov, 2014 May;4(5):592-605
  5. Riabinska A, Daheim M, Herter-Sprie GS, Winkler J, Fritz C, Hallek M, Thomas RK, Kreuzer KA, Frenzel LP, Monfared P, Martins-Boucas JM, Chen S, Reinhardt HC. Therapeutic targeting of a robust non-oncogene addiction to PRKDC in ATM-defective tumors. Sci Transl Med, 2013 Jun 12;5(189)
  6. Knittel G, Rehkämper T, Korovkina D, Liedgens P, Fritz C, Torgovnick A, Al-Baldawi Y, Al-Maarri M, Cun Y, Fedorchenko O, Riabinska A, Beleggia F, Nguyen P-H, Wunderlich FT, Ortmann M, Montesinos-Rongen M, Tausch E, Stilgenbauer S, Frenzel L, Herling M, Herling C, Bahlo J, Hallek M, Peifer M, Büttner R, Persigehl T, Reinhardt HC: Two mouse models reveal an actionable PARP1 dependence in aggressive chronic lymphocytic leukemia. Nature Communications, 2017 Jul 28;8(1):153. doi: 10.1038/s41467-017-00210-6.
  7. Knittel G, Liedgens P, Korovkina D, Seeger JM, Al-Baldawi Y, Al-Maarri M, Fritz C, Vlantis K, Bezhanova S, Scheel AH, Wolz OO, Reimann M, Möller P, López C, Schlesner M, Lohneis P, Weber ANR, Trümper L, ICGC MMML-Seq Consortium, Staudt LM, Ortmann M, Pasparakis M, Siebert R, Schmitt CA, Klatt AR, Wunderlich FT, Schäfer SC, Persigehl T, Montesinos-Rongen M, Odenthal M, Büttner R, Frenzel LP, Kashkar H, Reinhardt HC: B cell-specific conditional expression of Myd88p.L252P leads to the development of diffuse large B cell lymphoma in mice. Blood, 2016 Jun 2;127(22):2732-41. 
  8. Reinhardt HC, Aslanian AS, Lees JA, and Yaffe MB. p53 deficient cells rely on ATM and ATR-mediated checkpoint signaling through the p38 MAPK/MK2 pathway for survival after DNA damage. Cancer Cell, 2007 Feb;11(2):175-89.
  9. Reinhardt HC, Hasskamp P, Schmedding I, Morandell S, van Vugt M, Wang X, Linding R, Ong SE, Weaver D, Carr SA, Yaffe MB. DNA Damage activates A Spatially Distinct Late Cytoplasmic Cell Cycle Checkpoint Network Controlled by MK2-mediated RNA Stabilization. Mol Cell, 2010 Oct 8;40(1):34-49
  10. George J, Lim JS, Jang SJ, Cun Y, Ozretic L, Leenders F, Lu X, Fernandez-Cuesta L, Bosco G, Nguyen C, Berg J, Müller C, Dahmen I, Jahchan N, Yang D, Karnezis AN, Vaka D, Torres A, Menon R, Wang MS, Stuetz A, Korbel J, Wilkerson M, Hayes N, Engelmann D, Pützer B, Vlasic I, Seidel D, Pinther B, Schaub B, Becker C, Altmüller J, Yokota J, Khono T, Iwakawa R, Muley T, Peterson I, Chen Y, Soltermann A, Tischler V, Massion P, Zou Y, Wright GM, Russell P, Solomon B, Koch I, Field JK, Muscarella LA, La Torre A, Jakopovic M, Knezevic J, Heiden E, Roz L, Jovanovic D, Kontic M, Thunnissen E, Köhler J, Schuler M, Sanchez-Cespedes M, Salvesen H, Achter V, Bogus M, Schneider P, Zander T, Ansén S, Hallek M, Wolf J, Vingron M, Yatabe Y, Travis WD, Nürnberg P, Reinhardt HC, Perner S, Heukamp LC , Büttner R, Haas SA, Brambilla E, Peifer M, Sage J, Thomas RK. Comprehensive genomic profiling of small cell lung cancer. Nature, 2015 Aug 6;524(7563):47-53.

Patents

Inventors: Michael B. Yaffe, Isaac A. Manke, Daniel Lim, Hans Christian Reinhardt, USPTO Application #: 20090010927

Title: MAPKAP KINASE-2 AS A SPECIFIC TARGET FOR BLOCKING PROLIFERATION OF P53-DEFECTIVE CELLS

Abstract: The present invention relates to compounds and pharmaceutical compositions for treating cellular proliferative disorders, e.g., in patients having one or more p53-deficient cells, screening assays for identifying such compounds, and methods for treating such disorders